Oct 13, 2026 | Alternate Rx sourcing, Biosimilars, Drug costs, High-value formulary, MedBen Rx, Over-the-counter (OTC) drugs, Patient assistance, Specialty Drugs, Spending
Self-funded pharmacy plans rarely have just one cost concern. High-cost brands, combination products, specialty medications, and prescriptions that could be handled over the counter can all drive spending in different ways. Solutions exist, but many PBMs rely on...
Sep 29, 2026 | Brian Fargus, Brooke Hupp, Case Studies, Claims data, Conferences, Kurt Harden, Specialty Drugs
The 13th Annual Sherrill Morgan Healthcare Innovation Conference, held September 17-18, brought together employers from Ohio, Kentucky and Tennessee to discuss practical ways to manage health care costs. Chairman & CEO Kurt Harden, Vice President of Sales &...
Sep 28, 2026 | Artificial Intelligence, GLP-1s, High-cost claims, Neonatal conditions, Specialty Drugs, Stop-Loss, Trend
MedBen recetly noted that matching national trend in 2027 still means absorbing a large increase. A Fortune article points to the forces behind another year of elevated growth, including expensive drugs, high-cost treatments, and AI-enabled medical billing. Those same...
Aug 3, 2026 | Biosimilars, Cost Savings, Drug costs, Pharmacy, Prescription, Rx Costs, Savings, Specialty Drugs
Specialty drug costs are projected to jump another 32% by 2028, according to the Pharmacy Strategies Group. While greater utilization remains the primary driver, lower-cost biosimilars can help pharmacy plans offset the increase. Biosimilars’ overall market share...
Jul 3, 2026 | Acquisition Cost Index (ACI) pricing, Biosimilars, Client Report, Drug costs, Formularies, MedBen Rx, Rx Costs, Specialty Drugs, Spending, Transparency
U.S. pharmaceutical expenditures rose 12.7% in 2025 to $915.2 billion, according to a recent analysis in the American Journal of Health-System Pharmacy. Utilization drove most of the growth, led by high-cost therapies such as tirzepatide, semaglutide, and apixaban....
May 27, 2026 | Cancer, Claims, Client Report, GLP-1s, Heart disease, Specialty Drugs, Stop-Loss, Trend
A new Sun Life analysis shows high-cost claims continue to strain employer health plans. The annual High-Cost Claims and Injectable Drug Trends report identifies comorbid conditions, long inpatient stays, and injectable specialty drugs as primary drivers of claims...
